AAN Issues Guideline for Use of Antiseizure Meds in People of Childbearing Potential
By Elana Gotkine HealthDay Reporter
FRIDAY, May 17, 2024 -- In a practice guideline issued by the American Academy of Neurology, along with the American Epilepsy Society and the Society for Maternal-Fetal Medicine, recommendations are presented for the use of antiseizure medications (ASMs) among people with epilepsy of childbearing potential (PWECP). The guideline was published online May 15 in Neurology.
Alison M. Pack, M.D., M.P.H., from Columbia University in New York City, and colleagues developed evidence-based conclusions and recommendations relating to the effects of ASMs and folic acid supplementation on the prevalence of major congenital malformations (MCMs), adverse perinatal outcomes, and neurodevelopmental outcomes in children born to PWECP.
The authors note that at the earliest possible opportunity preconceptionally, clinicians should recommend ASMs and doses that optimize seizure control and fetal outcomes should pregnancy occur. The occurrence of convulsive seizures should be minimized in PWECP during pregnancy to reduce potential risks for the mother and fetus. Clinicians should exercise caution in attempting to remove or replace an ASM that is effective in controlling generalized tonic-clonic or focal-to-bilateral tonic-clonic seizures once a PWECP is already pregnant. To minimize the risk for MCMs, lamotrigine, levetiracetam, or oxcarbazepine should be considered when appropriate based on the patient's epilepsy syndrome, likelihood of achieving seizure control, and comorbidities. If clinically feasible, valproic acid should be avoided to minimize the risk for MCMs or neural tube defects; valproic acid should also be avoided to reduce the risk for poor neurodevelopmental outcomes, including autism spectrum disorder and lower IQ.
"Clinicians should prescribe at least 0.4 mg of folic acid supplementation daily preconceptionally and during pregnancy to any PWECP treated with an ASM to decrease the risk of neural tube defects and possibly improve neurodevelopmental outcomes in the offspring," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
In Utero Exposure to Antiseizure Meds Does Not Affect Child Creativity
WEDNESDAY, May 29, 2024 -- There are no differences in creative thinking at age 4.5 years for children of women with epilepsy (WWE) and children of healthy women (HW), but fetal...
American College of Obstetricians and Gynecologists, May 17-19
The annual meeting of the American College of Obstetricians and Gynecologists was held from May 17 to 19 in San Francisco and was attended by more than 4,000 clinicians...
First-Seizure Clinic Attendance Cuts Later Health Care Utilization
FRIDAY, May 24, 2024 -- First-seizure clinic (FSC) attendance is associated with reduced rates of subsequent health care utilization, according to a study published online May 23...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.